The content on this site is intended for healthcare professionals only
Dr Tim Rattay speaks to ecancer about a talk he presented at EBCC 2024 on new data from the PRE-ACT study. This study evaluates whether an AI tool can predict which breast cancer patients may be at risk of side effects after surgery and radiotherapy.
He explains that a type of 'explainable AI' was used and that the model produces predictions with associated explanations so that clinicians and patients can understand why there has been an identification of high risk.
Dr Rattay reports that the tool was able to accurately predict lymphoedema in almost 82% of patients.
Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
